SCHEMBL18628892

SCHEMBL18628892

CCOC(=O)c1c(C=O)ccnc1OCC(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.37
HCRTR2 O43614 3/20 0.37
JMJD6 Q6NYC1 2/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 7/20 0.36
USP2 O75604 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 1/20 0.36
PLA2G1B P04054 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18628910 0.89 HCRTR1 (0.37) HCRTR1HCRTR2JMJD6CA12CA1
SCHEMBL18628926 0.83 CA12 (0.40) HCRTR1HCRTR2JMJD6CA12CA1
SCHEMBL18628941 0.81 MAPT (0.37) JMJD6CA12CA1CA2CA7
SCHEMBL18628977 0.81 MAPT (0.37) JMJD6CA12CA1CA2CA7
SCHEMBL15729620 0.80 ALDH1A1 (0.42) CA12CA1CA2CA7CA9
SCHEMBL15729672 0.79 ALDH1A1 (0.37) JMJD6CA12CA1CA2CA7
SCHEMBL15729570 0.79 ALDH1A1 (0.40) HCRTR1HCRTR2JMJD6CA12CA1
SCHEMBL15729618 0.79 CA12 (0.42) JMJD6CA12CA1CA2CA7
SCHEMBL19443604 0.78 SMN1; SMN2 (0.47) JMJD6CA12CA1CA2CA7
SCHEMBL15729299 0.78 ALDH1A1 (0.35) JMJD6CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144308-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-06-24 EP disclosed
US-10208046-B2 Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-02-19 US disclosed
US-20170081332-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-23 US disclosed
EP-3144308-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208046-B2 Nitrogen-containing heterocyclic compound CHRM1, CHRM5, CHRM2 HCRTR1 46/4885HCRTR2 112/4885JMJD6 1336/4885
US-20170081332-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CHRM1, CHRM5, CHRM2 HCRTR1 46/4885HCRTR2 112/4885JMJD6 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.